July's initial public offerings (IPO) continue to bring more variety to a market that was mostly biotech companies during the beginning of the coronavirus pandemic throughout the second quarter. Last week saw the introduction of three companies as well as three special purpose acquisition companies (SPAC) as market participants are ready now more than ever to shake off pandemic uncertainty. This week fairs to be no different for the last, with two Chinese offerings and two biotechs set to debut.

To recap last week's market, familiar face Dun & Bradstreet Holdings Inc. (DNB  ) raised over $1.7 billion from pricing shares at $22 each in its initial offering. The commercial data analytics provider went private back in February 2019 and is now attempting to accelerate growth in its second debut. The company ended up 23%.

Online self-serve renters and homeowners insurance platform Lemonade Inc. (LMND  ) exploded onto the New York Stock Exchange, raising $319 million from pricing shares at $29 each. While highly unprofitable, the fast growing tech-enabled company wowed investors, finishing the week up 139%.

Healthcare benefits platform Accolade Inc. (ACCD  ) was not too far behind, raising over $220 million from pricing shares at $22 each. In the same situation at Lemonade when its comes to nature and profitability, the company finished its week up 35%.

In addition to the new stocks, three SPACs also tapped into public markets: Goldman Sachs's (GS  ) second blank check company GS Acquisition Holding II raised $700 million; Capstar Special Purpose Acquisition Corp. raised $240 million; and EcoR1 Capital's Panacea Acquisition Corp. raised $125 million.

Looking ahead, China's largest LGBTQ-focused dating app BlueCity Holdings plans to raise $85 million from 5.3 million offered shares in the range of $15-$17. The on-demand workers platform Quhuo, which serves as the largest workforce solutions platform in China, aims to raise $27 million from 2.7 million shares priced between $9-$11. Nkarta, a preclinical oncology biotech, is slated to raise $150 million from 10 million shares priced in the range of $14-$16. Finally, the Phase 2 oncology biotech Poseida Therapeutics plans to raise $150 million from 10 million shares priced between $14-$16.